Multitude Therapeutics, Inc., a clinical stage biopharmaceutical company focused on the development of ADC drugs, today announced interim results from its ongoing Phase I/II open-label, multicenter ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback